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The article by Allan et al 1 in Circulation is a commendable effort to assist the appropriate choice of cardiovascular risk score amid the numerous existing such tools. However, their findings of nonoptimal agreement between different calculators in pairwise comparisons are largely expected. The basis for selecting calculators, the methods for comparing them, and the premises of such comparisons are potentially flawed. For a study of this nature, one would expect the choice of calculators to be restricted to only those risk scores recommended for use in current guidelines, the usual entry point of decision rules into primary care practices, where the most benefit from the uptake of risk calculators is expected. Comparing risk estimates from calculators derived from different populations and countries, to predict outcomes defined differently over various timehorizons, without previous recalibration of these calculators to the baseline outcome risk in the target population may not be an optimal approach. Recalibration is very important to ensure that an existing model developed for a given population provides accurate estimates of the risk when applied to another population, likely with a different risk profile. 2, 3 Without recalibration, much of the variability attributable to differences in the frequency/levels of risk factors and outcomes in different populations will not be addressed, thus explaining a substantial part of the imperfect agreement reported by Allan et al. 1 Even with recalibration, it is very unlikely for models based on different sets of predictors to provide similar risk estimates at the individual level. However, such models may still provide similar estimates at the population levels, where benefits of cardiovascular risk reduction interventions are experienced. Furthermore, a hypothetical sample of 128 participants may be too small a population on which to base claims of agreement, because this may not reflect the whole spectrum of risk variability in a true population. Finally, in the application the UK Prospective Diabetes Study risk calculator, assuming a constant HbA 1c value of 5.2% and 0 years with diabetes mellitus for all nondiabetic participants, is rather simplistic and may not reflect the reality. Such an approach is limited in 2 ways. First, it creates a new predictor whose properties may differ from those of HbA 1c contributing predictive information across the whole spectrum of measurements. Second, a number of people with normal HbA 1c in the general population will actually have undiagnosed diabetes mellitus, notwithstanding the fact that caution is needed when applying general population-based cardiovascular risk models to contemporary populations with diabetes mellitus, in the light of existing evidence. 4 We applaud the attempts by the authors to identify the deficiencies of the numerous existing vascular risk calculators in providing comparable estimates of the absolute risk. However, comparisons of cardiovascular risk scores should use appropriate methodological approaches, including comparing calculators on the same footing. More effort is needed to test and adapt existing calculators to different settings, and to assess the effect of their uptake in clinical settings on prescriptions and outcomes of care.
